10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
English patients who have not responded to at least one other systemic therapy will soon be able to receive routine National Health Service prescriptions for a targeted biologic for moderate to severe atopic dermatitis, the most common type of eczema. 22 June 2018
USA-based biotech firm Heron Therapeutics saw its share rocket 30.13% to $39.95 after its revealed clinical data promising high hopes for its post-surgery pain treatment, as well as a coveted designation from the US regulars. 22 June 2018
The first ever application for a combination of two immuno-oncology (I-O) drugs in lung cancer has been accepted by the US Food and Drug Administration (FDA). 22 June 2018
The UK's Medicines and Healthcare products Regulatory Agency has renewed the Early Access to Medicines Scheme scientific opinion for Raxone (idebenone) for patients with Duchenne muscular dystrophy in respiratory function decline who are not taking glucocorticoids. 22 June 2018
At its 2018 Investor and Analyst Event, Incyte's (Nasdaq: INCY) recent suffering continued with the announcement that it planned to scrap one of its clinical trials. 21 June 2018
Lonsurf (trifluridine and tipiracil) leads to significant improvement in overall survival (OS) in patients with refractory metastatic gastric cancer, according to Phase III data. 21 June 2018
The US Food and Drug Administration (FDA) has added restrictions to the labels of two immunotherapy drugs for locally advanced or metastatic urothelial cancer patients who are not eligible for cisplatin-containing therapy. 21 June 2018
NeuroVive Pharmaceutical has entered into an exclusive licensing agreement with USA-based biotech BridgeBio Pharma for a subset of succinate prodrug chemistry under NeuroVive's NVP015 program. 21 June 2018
iTeos Therapeutics, a biotech developing novel cancer immunotherapies, has announced the completion of an oversubscribed $75 million Series B financing in the latest example of major investment in immuno-oncology (I-O). 20 June 2018
Proving their commercial viability is arguably the biggest barrier that gene therapies have to overcome, with the growing body of evidence and regulatory approvals showing that they are winning the battle to prove efficacy and safety. 20 June 2018
Independent mitochondrial DNA specialist Stealth BioTherapeutics has raised $100 million from Nan Fung Technology’s Pivotal Beta and other new and existing investors. 20 June 2018
US development stage company TG Therapeutics and privately-held Swiss firm Novimmune have entered into an exclusive global agreement to collaborate on the development and commercialization of Novimmune’s novel first-in-class anti-CD47/anti-CD19 bispecific antibody known as TG-1801 (previously NI-1701). 20 June 2018
The international medical humanitarian organization Médecins Sans Frontières (MSF) has filed a legal patent challenge at China’s State Intellectual Property Office (SIPO), requesting the invalidation of the patent granted to US pharmaceutical corporation Gilead Sciences (Nasdaq: GILD) for the oral hepatitis C medicine velpatasvir. 20 June 2018
Less than a week after setting up two new companies with a $35 million investment, life sciences trust Syncona is making more waves in gene therapy by contributing £85 million ($112 million) to Freeline Therapeutics' Series B funding campaign. 20 June 2018
US biotech major Amgen yesterday announced that the European Commission (EC) has granted a full marketing authorization for Blincyto (blinatumomab) based on the overall survival (OS) data from the Phase III TOWER study. 20 June 2018
Israel-based Galmed Pharmaceuticals has priced its previously announced underwritten public offering of 5,000,000 ordinary shares, at a public offering price of $15.00 per share. 20 June 2018
Sarepta Therapeutics saw its share price rocket following positive trial results for its lead gene therapy, targeting Duchenne muscular dystrophy (DMD). 19 June 2018
PTC Therapeutics saw its share price rise sharply over the weekend, following the revealing of encouraging data regarding the company's spinal muscular atrophy (SMA) treatment risdiplam. 19 June 2018
Novo Nordisk has announced a collaboration with Kallyope, a privately-held New York biotechnology platform developer, with the aim of developing novel therapies for diabetes and obesity. 19 June 2018
Solid Biosciences is back on track in its mission to deliver a gene therapy that dramatically changes the course of Duchenne muscular dystrophy (DMD). 19 June 2018
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024